If you’re pregnant, planning to be, or breastfeeding and considering BIMZELX (bimekizumab), you’re likely worried about safety—for yourself and your baby. This article unpacks what’s actually known (and what isn’t), shares expert opinions, real-world observations, and regulatory positions, and gives a clear, experience-driven take on whether BIMZELX is a safe option during these crucial times.
BIMZELX is a newer biologic therapy used for moderate-to-severe plaque psoriasis. But like many new treatments, there’s a lot we don’t know about its safety in pregnancy and breastfeeding. Many patients (and doctors) are left with vague guidelines, half-answers, and a lot of anxiety about whether to start, stop, or continue treatment. The aim here is to clarify what’s out there—and what’s not—using a mix of official data, clinical experience, and honest, practical insight.
First, let me set the scene. I had a real patient (let’s call her Emily) who was managing severe psoriasis with BIMZELX. She came in, beaming, and announced she was pregnant. Her dermatologist looked worried. “We don’t really have enough data,” she said. So Emily asked me: what should I do? Pause? Continue? Switch drugs? Stop everything? That’s when my deep dive began.
I pulled up the EMA Summary of Product Characteristics and the FDA label for BIMZELX. Both say almost the same thing: there are no adequate data on the use of bimekizumab in pregnant women. Animal studies suggest potential risks (like embryo-fetal toxicity at high doses), but these don’t always translate directly to humans. The official advice? Use only if the potential benefit justifies the potential risk to the fetus.
I checked the MotherToBaby fact sheet (these guys are the gold standard for pregnancy & medication info), and again: not enough human data. They recommend talking closely with your doctor, weighing risks and benefits.
I also trawled through forums (like National Psoriasis Foundation forums). One thread had a user who accidentally got pregnant on BIMZELX and was panic-Googling. Several people chimed in with “My doc switched me to cyclosporine” or “I stopped everything and risked a flare.” Not exactly scientific, but it shows the confusion and the tough decisions people face.
I called up Dr. Lisa Wang, a dermatologist I trust. Her take: “For most biologics, we have more data with the older ones like adalimumab or etanercept during pregnancy, but bimekizumab is too new. Unless the patient’s symptoms are totally unmanageable, I’d hold off during pregnancy and breastfeeding. But if it’s the only thing that works, it’s a case-by-case call.” She pointed to the AAD guidelines, which echo this cautious approach.
In contrast, a rheumatology colleague said, “We sometimes keep patients on biologics during pregnancy if their disease is severe—risk of uncontrolled inflammation can be worse than the theoretical drug risk.”
Here’s how I’d approach this if you were a friend asking me over coffee (not as your doctor, but as someone who’s been around the block with these meds):
True story: I once mixed up which biologic a patient was on and nearly gave the wrong advice—so always double check the exact medication, since “biologics” aren’t all the same.
Emily, my patient, ended up pausing BIMZELX after a consult with her OB and dermatologist. She had a mild flare but managed it with topical steroids. Her baby was born healthy. Later, she chose a different, older biologic with more pregnancy data for postpartum management. Her experience matches what’s reflected in registry data so far: most doctors play it safe and switch or pause BIMZELX for pregnancy and breastfeeding.
Let’s get nerdy for a second. Here’s what the big agencies say, with links so you can fact-check:
| Country/Region | Official Position | Legal Basis | Responsible Authority |
|---|---|---|---|
| USA | Not recommended; insufficient data | FDA Labeling (21 CFR 201.57) | FDA |
| EU | Not recommended unless clearly needed | EMA Summary of Product Characteristics | EMA |
| UK | Avoid; insufficient data | MHRA Guidance | MHRA |
| Australia | Category B1 (limited data; avoid) | TGA Prescribing Info | TGA |
Dr. Sofia Gutierrez, who runs a pregnancy-dermatology clinic, told me: “Patients are often surprised that we don’t have all the answers. With bimekizumab, we stick to older biologics for now. If someone’s on it and planning pregnancy, we switch them off. If they’re already pregnant, we stop and monitor closely. We document everything—it’s all about balancing risks, and right now, we just don’t have enough data for comfort.”
Here’s the bottom line: BIMZELX is not recommended during pregnancy or breastfeeding due to lack of data. All the major regulatory agencies (FDA, EMA, etc.) say the same thing: only use if the benefit clearly outweighs the risk, and ideally, choose something else. If you’re already on BIMZELX and get pregnant, don’t panic—call your doctor, discuss your options, and don’t make any sudden changes without professional advice.
My personal reflection? The lack of data is frustrating for patients and doctors alike. Until better pregnancy registries or post-marketing studies come out, the safest option is to avoid BIMZELX if you’re pregnant or breastfeeding. If you absolutely need it, make sure your care team is on the same page and monitoring you closely.
Next steps: If you’re in this situation, set up a multi-specialty meeting with your dermatologist and OB. Bring them these links, ask about safer alternatives like certolizumab (which does have reassuring pregnancy data), and don’t be afraid to get a second opinion.
References: